The exclusive NZMP strains of Bifidobacterium animalis subspecies lactis HN019 (BifidoB HN019TM) and Lacticaseibacillus rhamnosus HN001* (LactoB HN001TM) have been clinically demonstrated to offer consumers digestive health and immunity benefits by adding intestinal barrier and eliminating the threat of certain diseases. infections and inflammations. Isolated from the microbial cultures used in the manufacture of yogurt and cheese, these dairy-free strains have been developed to meet 3 criteria: safe, effective and stable. With a wide diversity of clinical studies to highlight its quality, the probiotic from NZMP strains are suitable for a variety of applications, adding ready-to-mix powdered beverages, supplements, chocolates, protein bars or coated snacks, yogurts, ice cream, cheeses, new fruit juices or fermented dairy drinks.
As the first discoverer of the probiotics HN001 ™ and HN019 ™, Fonterra promoted those super strains in the 90s and continues to own the brand, so it’s not unexpected that the company has invested in human clinical studies. Clinical evidence from a number of trials employing physically powerful reference methodologies has led to extensive studies on the HN001 ™ and HN019 supercepas ™ in humans. Human clinical evidence from all generations and markets offers the NZMP exclusive credit to American consumers by occasionally looking for providers who can offer clinical benefits to consumers. The NZMP continues to invest in studies, giving consumers confidence that these strains will help them differentiate themselves in the market as consumers become more informed about their food choices.